Ashwani Verma
Stock Analyst at UBS
(2.17)
# 2,657
Out of 4,784 analysts
64
Total ratings
39.13%
Success rate
-1.86%
Average return
Main Sectors:
Stocks Rated by Ashwani Verma
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JAZZ Jazz Pharmaceuticals | Upgrades: Buy | $145 → $179 | $122.92 | +45.62% | 6 | Mar 7, 2025 | |
| ALKS Alkermes | Upgrades: Neutral | n/a | $33.21 | - | 3 | Mar 4, 2025 | |
| TEVA Teva Pharmaceutical Industries | Maintains: Buy | $30 → $27 | $15.08 | +79.05% | 8 | Jan 30, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $162 → $176 | $113.16 | +55.53% | 6 | Jan 30, 2025 | |
| EXEL Exelixis | Maintains: Neutral | $30 → $34 | $36.70 | -7.36% | 2 | Jan 28, 2025 | |
| AVDL Avadel Pharmaceuticals | Maintains: Buy | $22 → $14 | $8.01 | +74.78% | 2 | Jan 13, 2025 | |
| UTHR United Therapeutics | Maintains: Buy | $415 → $475 | $306.97 | +54.74% | 4 | Jan 8, 2025 | |
| ACLX Arcellx | Maintains: Buy | $106 → $114 | $67.96 | +67.75% | 2 | Dec 10, 2024 | |
| HRMY Harmony Biosciences Holdings | Initiates: Buy | $56 | $33.19 | +68.73% | 1 | Sep 10, 2024 | |
| CHRS Coherus BioSciences | Downgrades: Neutral | $4 → $1.5 | $0.84 | +78.87% | 4 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $55 → $54 | $27.65 | +95.30% | 3 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $83 → $79 | $131.81 | -40.07% | 5 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $23 | $17.07 | +34.74% | 3 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $107 → $105 | $118.53 | -11.41% | 2 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $28 | $31.37 | -10.74% | 3 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $76 → $81 | $35.06 | +131.03% | 2 | Mar 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $61 → $92 | $43.19 | +113.01% | 4 | Jan 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $7 | $65.73 | -89.35% | 1 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $9 → $12 | $8.68 | +38.25% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $1.36 | +1,002.94% | 1 | Oct 11, 2022 |
Jazz Pharmaceuticals
Mar 7, 2025
Upgrades: Buy
Price Target: $145 → $179
Current: $122.92
Upside: +45.62%
Alkermes
Mar 4, 2025
Upgrades: Neutral
Price Target: n/a
Current: $33.21
Upside: -
Teva Pharmaceutical Industries
Jan 30, 2025
Maintains: Buy
Price Target: $30 → $27
Current: $15.08
Upside: +79.05%
Neurocrine Biosciences
Jan 30, 2025
Maintains: Buy
Price Target: $162 → $176
Current: $113.16
Upside: +55.53%
Exelixis
Jan 28, 2025
Maintains: Neutral
Price Target: $30 → $34
Current: $36.70
Upside: -7.36%
Avadel Pharmaceuticals
Jan 13, 2025
Maintains: Buy
Price Target: $22 → $14
Current: $8.01
Upside: +74.78%
United Therapeutics
Jan 8, 2025
Maintains: Buy
Price Target: $415 → $475
Current: $306.97
Upside: +54.74%
Arcellx
Dec 10, 2024
Maintains: Buy
Price Target: $106 → $114
Current: $67.96
Upside: +67.75%
Harmony Biosciences Holdings
Sep 10, 2024
Initiates: Buy
Price Target: $56
Current: $33.19
Upside: +68.73%
Coherus BioSciences
Aug 16, 2024
Downgrades: Neutral
Price Target: $4 → $1.5
Current: $0.84
Upside: +78.87%
Aug 13, 2024
Maintains: Buy
Price Target: $55 → $54
Current: $27.65
Upside: +95.30%
Aug 8, 2024
Maintains: Neutral
Price Target: $83 → $79
Current: $131.81
Upside: -40.07%
Aug 8, 2024
Maintains: Buy
Price Target: $25 → $23
Current: $17.07
Upside: +34.74%
Aug 6, 2024
Maintains: Buy
Price Target: $107 → $105
Current: $118.53
Upside: -11.41%
Jun 3, 2024
Downgrades: Neutral
Price Target: $28
Current: $31.37
Upside: -10.74%
Mar 18, 2024
Maintains: Buy
Price Target: $76 → $81
Current: $35.06
Upside: +131.03%
Jan 24, 2024
Downgrades: Neutral
Price Target: $61 → $92
Current: $43.19
Upside: +113.01%
Aug 7, 2023
Maintains: Buy
Price Target: $11 → $7
Current: $65.73
Upside: -89.35%
Nov 10, 2022
Upgrades: Neutral
Price Target: $9 → $12
Current: $8.68
Upside: +38.25%
Oct 11, 2022
Initiates: Buy
Price Target: $15
Current: $1.36
Upside: +1,002.94%